Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05382741
Title Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial (VIVA)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Ospedale Policlinico San Martino
Indications

colorectal adenocarcinoma

Therapies

Durvalumab + Regorafenib

Age Groups: adult | senior
Covered Countries ITA

Additional content available in CKB BOOST